Donghai Men1, Yuansheng Liang2, Liyi Chen3. 1. Department of Neurosurgery, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, China. Electronic address: 475080010@qq.com. 2. Department of Neurosurgery, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, China. Electronic address: lys845@163.com. 3. Department of Neurosurgery, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, China. Electronic address: lysghq@163.com.
Abstract
BACKGROUND AND AIM: As a member of the microRNA (miR)-200 family, miR-200b has been recognized as one of the fundamental regulators of epithelial-mesenchymal transition, chemosensitivity, cell proliferation, and cell cycle. Especially in glioma, miR-200b targets the CREB1 gene and suppresses the tumor cell growth in vitro. However, its involvement in human glioma has not yet been determined. The aim of this study was to investigate the clinical significance of miR-200b expression in this disease. METHODS: miR-200b expression in 266 pairs of human gliomas and matched nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. RESULTS: Compared with nonneoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs. normal: 2.87 ± 2.05 vs. 8.78 ± 2.50, P<0.001). Of 266 patients with gliomas, 166 (62.41%) were in low miR-200b expression group. In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II). Moreover, the expression level of miR-200b was positively correlated with Karnofsky performance status (KPS) scores of glioma tissues. The results of a 60-month follow-up in 266 glioma patients further demonstrated that lower miR-200b expression was correlated with worse progression-free survival and overall survival in the patients with grade III and IV gliomas. Both univariate and multivariate analyses revealed that miR-200b was an independent prognostic indicator for glioma. CONCLUSION: These findings prove that the decreased expression of miR-200b may be associated with malignant tumor progression and poor prognosis in patients with gliomas, suggesting the potential role of miR-200b in glioma management. miR-200b may be a novel and valuable signature for predicting the clinical outcome of patients with gliomas.
BACKGROUND AND AIM: As a member of the microRNA (miR)-200 family, miR-200b has been recognized as one of the fundamental regulators of epithelial-mesenchymal transition, chemosensitivity, cell proliferation, and cell cycle. Especially in glioma, miR-200b targets the CREB1 gene and suppresses the tumor cell growth in vitro. However, its involvement in humanglioma has not yet been determined. The aim of this study was to investigate the clinical significance of miR-200b expression in this disease. METHODS:miR-200b expression in 266 pairs of humangliomas and matched nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. RESULTS: Compared with nonneoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs. normal: 2.87 ± 2.05 vs. 8.78 ± 2.50, P<0.001). Of 266 patients with gliomas, 166 (62.41%) were in low miR-200b expression group. In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II). Moreover, the expression level of miR-200b was positively correlated with Karnofsky performance status (KPS) scores of glioma tissues. The results of a 60-month follow-up in 266 gliomapatients further demonstrated that lower miR-200b expression was correlated with worse progression-free survival and overall survival in the patients with grade III and IV gliomas. Both univariate and multivariate analyses revealed that miR-200b was an independent prognostic indicator for glioma. CONCLUSION: These findings prove that the decreased expression of miR-200b may be associated with malignant tumor progression and poor prognosis in patients with gliomas, suggesting the potential role of miR-200b in glioma management. miR-200b may be a novel and valuable signature for predicting the clinical outcome of patients with gliomas.
Authors: Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor Journal: J Neurooncol Date: 2015-09-21 Impact factor: 4.130